GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - REZOLUTE INC

Explicit Guidance:

• BLA Filing: Planning to file a Biologics License Application (BLA) for the congenital hyperinsulinism (CHI) indication in the middle of next year (2026).
• Regulatory Timelines (Conservative Path): Aims for a Pediatric Advisory Committee (PAC) meeting for CHI in Q1 2028; anticipates a Pediatric Advisory Committee meeting for the tumor indication (THI) approximately nine months later (late 2028) under a Supplemental Biologics License Application (sBLA).
• Regulatory Timelines (Accelerated Path): Acknowledges the possibility of a truncated timeline for the tumor indication if the FDA agrees to accelerate approval due to unmet need, though this is contingent on upcoming agency discussions.
• Financial Position: Current cash balance of $90 million is sufficient to operate and grow the company through the current phase but explicitly noted as insufficient to fund the launch of both indications; significant capital raising is anticipated.

Business-Segment Outlook:

• Congenital Hyperinsulinism (CHI): Total Addressable Market (TAM) estimated at 2,000 patients (1,500 diazoxide-nonresponsive + 40% of diazoxide-responders with recurrent hypoglycemia). Expected to be the first indication to launch.
• Tumor-Associated Hyperinsulinism (THI): Total Addressable Market (TAM) estimated at 4,000 patients (2,500 for insulinoma + 1,500 for Non-Islet Cell Tumor Hypoglycemia [NICTH]).
• Total Combined TAM: Projected at 6,000 patients across both indications with a financial opportunity well north of $5 billion.
• Pricing Strategy: Anticipates "ultra-rare" pricing for both indications. Due to weight-based dosing, the tumor indication (patients 2–3x the weight of pediatric CHI patients) will command a higher per-patient price, potentially in the "hundreds of thousands" range per patient.
• Launch Cadence: Sequential launch strategy; congenital indication first, followed by the tumor indication.

Market and Competitive Outlook:

• Demand Trends: Management expects patients to migrate to the therapy upon launch; identifies a massive unmet need in both populations, particularly for patients refractory to existing therapies (diazoxide, steroids, somatostatin analogs).
• Competitive Landscape: No direct competitors for refractory hypoglycemia associated with these specific tumor types; DIAZOXIDE is noted as ineffective for NICTH.
• Payer Impact: Projected to have a minimal budget impact for individual payers due to the ultra-rare nature (typically 1–2 patients per payer), suggesting strong payer willingness to cover at premium pricing.
• Market Access: Commercial footprint optimized for concentration; targeting ~80-90% of patients via 500 pediatric endocrinologists (CHI) and ~60% via 1,000 adult endocrinologists and 65 National Cancer Institute (NCI) sites (THI).

Macro / Industry Outlook:

• Regulatory Environment: Management views the current FDA stance on rare diseases as highly supportive, citing a willingness to accept single-arm, open-label study designs (for THI) and revised endpoints (CGM data vs. finger sticks for CHI) when robust real-world evidence exists.
• Economic Context: Acknowledges a potential disconnect between the company's current market cap (sub-$500 million) and its projected TAM ($5+ billion), attributing this to recent Phase 3 data headwinds (Sunrise study) and the time required for market recognition.

Strategic Initiatives:

• Commercial Ramp-Up: Building a lean commercial team of 10–15 salespeople for the congenital indication, with a separate potential team for the adult tumor indication.
• Patient Identification: Leveraging machine learning to pinpoint specific physicians and institutions treating the target patient populations (e.g., in Minnesota, Iowa, San Diego) to optimize patient finding.
• M&A/Capital Strategy: No specific M&A announced; explicitly stated need to address balance sheet through significant new capital raising to fund launch activities.
• Timeline: Full commercial organization ramping up in preparation for a 2028 launch window.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: The final timeline for the tumor indication (sBLA) is unknown and contingent on the outcome of pre-BLA meetings in early 2026.
• Study Design Risk: Reliance on single-arm, open-label studies for the tumor indication; while FDA-aligned, any deviation from expected efficacy (50% reduction in glucose infusion) could jeopardize approval.
• Enrollment Challenges: Uplift study enrollment is slow; however, management maintains this is typical for ultra-rare diseases and does not reflect the total available population.
• Execution Risk: Launching two distinct indications (pediatric and adult) sequentially with limited cash reserves creates significant execution and capital timing pressure.

Management Tone on the Future:

• Confidence: High confidence in efficacy based on Real-World Evidence (EAP) showing "profound change" in outcomes and a "50 to 75%" difference in efficacy vs. placebo in the congenital cohort.
• Sentiment: "Emboldened" and "excited." Management expresses strong belief that the market dislocation (market cap vs. value) will close as the "lights go on" regarding the drug's potential.
• Caveats: Acknowledges the "Sunrise study" placebo confounder as a past hurdle but frames the current trajectory as a recovery from that event, leveraging the unique data set to move forward.